Oncology Drug Reference Sheet: Elranatamab-Bcmm
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
Voice
Description
Elranatamab-bcmm, an immunotherapy indicated for relapsed or refractory multiple myeloma, received accelerated approval in 2023. It is a bispecific antibody and T-cell engager that binds to BCMA, which occurs on the surface of myeloma and other cells, and CD3, which occurs on T cells, causing cytokine release and myeloma cell lysis. This ONS resource was produced for educational purposes only. Refer to the full elranatamab-bcmm (Elrexfio™) package insert for all details.